Kyntra Bio, Inc. (KYNB): Total Assets
$119.59M
As of 2025-12-31
$101.08M
As of 2026-06-30
-41.9%
3-year compound annual growth
-32.1%
5-year compound annual growth
-12.8%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $119.59M | -44.3% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $214.53M | -49.3% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $423.53M | -30.6% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $610.09M | -21.2% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $773.82M | -6.4% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $826.84M | -3.6% | 2022-03-04, Balance as of period end |
| 2019-12-31 | $857.40M | -2.6% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $880.60M | -2.0% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $898.65M | +91.4% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $469.55M | -0.2% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $470.57M | -2.7% | 2017-03-01, Balance as of period end |
| 2014-12-31 | $483.53M | n/a | 2016-02-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | $119.59M | -44.3% |
| Filana Therapeutics, Inc. (FLNA) | 2025-12-31 | $118.36M | -24.9% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $117.81M | +50.4% |
| Aardvark Therapeutics, Inc. (AARD) | 2025-12-31 | $117.18M | +51.2% |
| PMV Pharmaceuticals, Inc. (PMVP) | 2025-12-31 | $116.56M | -39.1% |
| Sagimet Biosciences Inc. (SGMT) | 2025-12-31 | $116.48M | -27.3% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $116.46M | -22.7% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $114.11M | +17.8% |
| Milestone Pharmaceuticals Inc. (MIST) | 2025-12-31 | $113.56M | +50.4% |
Compare KYNB, FLNA, CAMP, AARD side by side · Screen every company in Pharmaceutical Preparations ↗